Skip to main content

Table 4 Associations between adverse eventsa, regimen, age, and immunosuppression, n = 726

From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Covariates

 

Univariable

Multivariable

n

c OR

p

a OR

SE

p

95% CI

Regimen (Wald test for overall variable in adjustment model, p = 0.065)

 3RHb

399

1 (ref)

 

1 (ref)

   

 3RPHc

306

0.57

0.097

0.60

0.209

0.141

0.30–1.18

 Otherd

21

3.99

0.012

2.37

1.360

0.131

0.78–7.30

Age

 < 35 yrs

561

1 (ref)

 

1 (ref)

   

 > 35 yrs

165

3.62

< 0.001

2.51

2.25

0.024

1.13–5.60

Immunosuppression

 No immunosuppression

603

1 (ref)

 

1 (ref)

   

 Immunosuppression, any

123

3.39

< 0.001

1.55

0.66

0.306

0.67–3.57

  1. OR Odds ratio, SE standard error
  2. aAdverse effects leading to termination or interruption of treatment, n = 47
  3. b3HR, 3 months daily rifampicin and isoniazid
  4. c3RPH, 12 weekly doses of rifapentine and isoniazid
  5. dOther; rifampicin monotherapy (n = 5), isoniazid monotherapy (n = 13), combination therapy for TB disease (n = 2) and 1 missing information